PL3592355T3 - Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego - Google Patents

Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego

Info

Publication number
PL3592355T3
PL3592355T3 PL18764980.1T PL18764980T PL3592355T3 PL 3592355 T3 PL3592355 T3 PL 3592355T3 PL 18764980 T PL18764980 T PL 18764980T PL 3592355 T3 PL3592355 T3 PL 3592355T3
Authority
PL
Poland
Prior art keywords
keratis
actinic
treatment
actinic keratis
Prior art date
Application number
PL18764980.1T
Other languages
English (en)
Inventor
Min-fun Rudolf Kwan
Johnson Yiu-Nam Lau
E. Douglas Kramer
David Lawrence CUTLER
Jane FANG
Original Assignee
Atnx Spv, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3592355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv, Llc filed Critical Atnx Spv, Llc
Publication of PL3592355T3 publication Critical patent/PL3592355T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
PL18764980.1T 2017-03-10 2018-03-12 Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego PL3592355T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
PL3592355T3 true PL3592355T3 (pl) 2026-04-07

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18764980.1T PL3592355T3 (pl) 2017-03-10 2018-03-12 Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego

Country Status (22)

Country Link
US (3) US10617693B2 (pl)
EP (2) EP4659740A3 (pl)
JP (3) JP7502863B2 (pl)
KR (2) KR20240090837A (pl)
CN (1) CN110891575A (pl)
AU (2) AU2018231144B2 (pl)
BR (1) BR112019018687A2 (pl)
CA (1) CA3055938A1 (pl)
DK (1) DK3592355T3 (pl)
ES (1) ES3060528T3 (pl)
FI (1) FI3592355T3 (pl)
HR (1) HRP20260155T1 (pl)
IL (1) IL269182B2 (pl)
LT (1) LT3592355T (pl)
MX (2) MX387658B (pl)
PL (1) PL3592355T3 (pl)
PT (1) PT3592355T (pl)
RS (1) RS67713B1 (pl)
SI (1) SI3592355T1 (pl)
TW (1) TWI841523B (pl)
WO (1) WO2018165647A1 (pl)
ZA (1) ZA202100106B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
SI3592355T1 (sl) 2017-03-10 2026-04-30 Atnx Spv, Llc KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US11752156B2 (en) * 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
CN101687798B (zh) 2007-05-17 2012-08-15 金克斯医药品有限公司 制备用于调节激酶级联的组合物的过程及其使用方法
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
EP2378876B1 (en) * 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
SI3592355T1 (sl) * 2017-03-10 2026-04-30 Atnx Spv, Llc KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Also Published As

Publication number Publication date
HRP20260155T1 (hr) 2026-03-27
PT3592355T (pt) 2026-02-03
DK3592355T3 (da) 2026-02-16
BR112019018687A2 (pt) 2020-04-07
EP3592355B1 (en) 2025-12-10
RU2019131757A3 (pl) 2021-05-31
TWI841523B (zh) 2024-05-11
NZ757105A (en) 2026-02-27
JP7502863B2 (ja) 2024-06-19
AU2018231144A1 (en) 2019-10-03
IL269182B1 (en) 2023-07-01
EP4659740A3 (en) 2026-02-18
MX2019010707A (es) 2020-01-15
TW201842913A (zh) 2018-12-16
US11497750B2 (en) 2022-11-15
ES3060528T3 (en) 2026-03-26
SI3592355T1 (sl) 2026-04-30
MX387658B (es) 2025-03-18
AU2024201828A1 (en) 2024-05-02
AU2018231144B2 (en) 2023-12-21
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
CN110891575A (zh) 2020-03-17
IL269182A (en) 2019-11-28
FI3592355T3 (fi) 2026-02-13
WO2018165647A1 (en) 2018-09-13
EP3592355A4 (en) 2021-01-06
AU2024201828B2 (en) 2026-02-19
EP3592355A1 (en) 2020-01-15
JP2020510042A (ja) 2020-04-02
RS67713B1 (sr) 2026-02-27
ZA202100106B (en) 2022-08-31
US20230172942A1 (en) 2023-06-08
KR20190141661A (ko) 2019-12-24
IL269182B2 (en) 2023-11-01
EP4659740A2 (en) 2025-12-10
JP2023015269A (ja) 2023-01-31
LT3592355T (lt) 2026-02-25
US20180256589A1 (en) 2018-09-13
KR20240090837A (ko) 2024-06-21
RU2019131757A (ru) 2021-04-12
US12667576B2 (en) 2026-06-30
CA3055938A1 (en) 2018-09-13
US10617693B2 (en) 2020-04-14
JP2025029010A (ja) 2025-03-05

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL282663A (en) Bt1718 for use in treating cancer
IL269371A (en) Treatment methods
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
PL3681872T3 (pl) Podstawione heteroarylem beta-hydroksyetylaminy do stosowania w leczeniu hiperglikemii
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
SI3518783T1 (sl) Naprava za zmanjševanje tkiva
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
PL3481846T3 (pl) 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
DK3474802T3 (da) Medicinsk forbinding
EP3858943A4 (en) Surface treatment agent
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3431566A4 (en) SURFACE TREATMENT AGENT
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
PL3432872T3 (pl) Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL251904B (en) Apilimod for use in the treatment of melanoma
EP3630331C0 (en) FLUID TREATMENT
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL260373B (en) Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP3597225A4 (en) TREATMENT PROCESS